Today’s drug pricing trends, particularly in the specialty drug sector, seriously threaten the affordability of health care in the United States. For years, patients and purchasers have shouldered prices of more than $100,000 a year for certain medicines – particularly those that treat relatively rare disorders. But in a concerning new development, the industry is increasingly applying rare-disease pricing to treatments for diseases afflicting millions: hepatitis, cancer, high cholesterol, multiple sclerosis, and diabetes. If this trend is left unchecked, American health care will soon face an untenable choice: reduce access to medications needed to manage common chronic conditions or face increasingly unaffordable cost burdens.
That’s why NCHC and our 501 c4 affiliate the NCHC Action Fund have launched the Campaign for Sustainable Rx Pricing. a non partisan coalition of organizations informing the debate on drug pricing and finding bipartisan, market-based solutions to lower drug prices in the U.S. Members represent hospitals, physicians, nurses, consumers, health plans, pharmacists, and employers.
Recent Publications from NCHC on this topic:
See CSRxP’s proposals for change here.